Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer
Sanofi wasn’t the only party interested in Teva’s anti-TL1A antibody, but it emerged as the “perfect partner” to secure a deal worth up to $1.5 billion, according to Teva’s CEO Richard Francis.
The Israel-based company is set to receive €469 million ($500 million) upfront and up to €940 million ($1 billion) in development and launch milestones, the companies revealed early Wednesday morning.
In the anti-TL1A contest, Roivant is already in the mix when it teamed up with Pfizer for RVT-3101, as is Merck, which bought Prometheus Biosciences in a deal worth $10.8 billion for MK-7240.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
